Literature DB >> 2322617

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

G C Siek1, L S Katz, E B Fishman, T S Korosi, J K Marquis.   

Abstract

We have previously reported that the 10s molecular form (G4) of acetylcholinesterase (AChE) is selectively lost from several cortical areas of Alzheimer's disease (AD) brain. In the current follow-up study, we microdissected several areas of nondemented and AD brain, including the hippocampus, amygdala, and cingulate gyrus. Tissue homogenates were separated on sucrose density gradients and the resulting fractions were analyzed for AChE activity in order to define the ratios of the predominant AChE molecular forms (G4/G1). Both the hippocampus and amygdala exhibited distinct patterns of alterations in the G4/G1 ratio which correlate with the known distribution of histopathological changes in AD brain. In order to further define the major pool of AChE that is depleted in AD, we separated fractionated tissue homogenates into salt-soluble and detergent-soluble fractions. The G4/G1 ratios were only altered in the detergent-soluble fractions, indicating that the loss of the G4 AChE molecular form involves a selective depletion of the membrane pool. Available evidence would suggest that this form is the AChE molecular form physiologically relevant at the cholinergic synapse.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2322617     DOI: 10.1016/0006-3223(90)90524-6

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

Review 1.  Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.

Authors:  George T Grossberg
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Alpha rhythm oscillations and MMSE scores are differently modified by transdermal or oral rivastigmine in patients with Alzheimer's disease.

Authors:  Davide V Moretti
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

3.  Colocalization of cholinesterases with beta amyloid protein in aged and Alzheimer's brains.

Authors:  M A Morán; E J Mufson; P Gómez-Ramos
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  Preferential inhibition of acetylcholinesterase molecular forms in rat brain.

Authors:  N Ogane; E Giacobini; E Messamore
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

Review 5.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 6.  Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase.

Authors:  Hai Yan Zhang; Han Yan; Xi Can Tang
Journal:  Cell Mol Neurobiol       Date:  2007-07-27       Impact factor: 5.046

7.  A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease.

Authors:  Agneta Nordberg; Clive Ballard; Roger Bullock; Taher Darreh-Shori; Monique Somogyi
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-07

8.  Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.

Authors:  George T Grossberg
Journal:  Curr Ther Res Clin Exp       Date:  2003-04

9.  Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Authors:  Agneta Nordberg; Taher Darreh-Shori; Elaine Peskind; Hilkka Soininen; Malahat Mousavi; Gina Eagle; Roger Lane
Journal:  Curr Alzheimer Res       Date:  2009-02       Impact factor: 3.498

Review 10.  Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.

Authors:  Changiz Geula; Sara R Dunlop; Ivan Ayala; Allegra S Kawles; Margaret E Flanagan; Tamar Gefen; Marek-Marsel Mesulam
Journal:  J Neurochem       Date:  2021-08-06       Impact factor: 5.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.